Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage clinical trials.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency Versus Other Amyloid Beta-Directed Antibodies
ProMis Neurosciences Inc. reported further results of its previously announced and ongoing preclinical program for Alzheimer’s disease.
A sound-emitting device worn in the ear during sleep may train the brain to ignore an annoying chronic ringing in the ears, a new study suggests.
Research carried out in part by an artificially intelligent ‘robot scientist’ found that a common ingredient of toothpaste could be developed to fight drug-resistant strains of malaria.
A heated chemotherapy organ bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer.
Cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival at the planned second interim analysis for the population of second-line and third-line patients enrolled in the CELESTIAL study.
Eiger BioPharmaceuticals Inc. will stop development of a drug to treat pulmonary arterial hypertension after it failed in a mid-stage study.
A cocktail of Merck & Co. Inc.’s blockbuster drug Keytruda and two chemo medicines helped lung cancer patients live longer and stopped the disease from advancing.
Novartis new data reinforces superiority of Cosentyx versus Stelara in achieving skin clearance for psoriasis patients
Novartis announced results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering clear and almost clear skin in adults with moderate to severe plaque psoriasis at 12 weeks.
Socially isolated people may be more likely to develop diabetes than adults with closer ties to family and friends, a recent study suggests.
Human antibodies made in genetically engineered cows have proved safe in an early-stage clinical trial.
Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.
Sangamo Therapeutics Inc. and Pfizer Inc. are partnering to develop a gene therapy to treat a disease that affects nerve cells in the brain and the spinal cord.
Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.
People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.
Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.
Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who do not use these supplements per a research review.
Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.
The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.